ID.1
Item
diagnosed with type 2 diabetes.
boolean
C0011860 (UMLS CUI [1])
ID.2
Item
have been exposed to exenatide for at least 3 months in previous amylin/lilly studies h8o-mc-gwao, h8o-mc-gwap, h8o-mc-gwat, or h8o-mc-gwba.
boolean
C0167117 (UMLS CUI [1])
ID.3
Item
have interrupted exenatide treatment for a period of at least 2 months.
boolean
C0167117 (UMLS CUI [1])
ID.4
Item
hba1c of ≤10.5%.
boolean
C0019018 (UMLS CUI [1])
ID.5
Item
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
boolean
C0087111 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
ID.6
Item
have previously completed or withdrawn from this study.
boolean
C2348557 (UMLS CUI [1,1])
C2348571 (UMLS CUI [1,2])
ID.7
Item
have taken marketed exenatide (byetta) during the interim period between studies gwao, gwap, gwat, or gwba and the current study.
boolean
C1636686 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
ID.8
Item
used drugs for weight loss (for example, xenical® [orlistat], meridia® [sibutramine], acutrim® [phenylpropanolamine], accomplia® [rimonabant], or similar over-the-counter medications) within 3 months of screening.
boolean
C0376606 (UMLS CUI [1])
ID.9
Item
are currently treated with any of the following excluded medications: drugs that directly affect gastrointestinal motility, including, but not limited to: reglan®
boolean
C0034977 (UMLS CUI [1,1])
C0017184 (UMLS CUI [1,2])
ID.10
Item
(metoclopramide), propulsid® (cisapride), and chronic macrolide antibiotics.
boolean
C0025853 (UMLS CUI [1,1])
C0722861 (UMLS CUI [1,2])
C0003240 (UMLS CUI [1,3])
ID.11
Item
use insulin with daily dosage exceeding 1 u/kg.
boolean
C0021641 (UMLS CUI [1])